Common neural underpinnings identified for sleep disturbances associated with obsessive-compulsive spectrum, chronic tic, and attention deficit-hyperactivity disorders

May 12, 2025 —Increased sleep difficulties in patients with obsessive-compulsive spectrum disorders (OCSDs), chronic tic disorders (CTDs), and attention-deficit/hyperactivity disorder (ADHD) are likely due to disruptions in the cortico-striatal-thalamo-cortical (CSTC) pathway, according to a narrative review in the May issue of Harvard Review of Psychiatry, part of the Lippincott portfolio from Wolters Kluwer.

Margaret D. Hall at Miami University in Oxford, Ohio, Erica Greenberg, MD and Kevin Gipson, MD, MS, at Massachusetts General Hospital, and colleagues also report evidence that dopamine and GABA—primary neurotransmitters in CSTC circuitry—are dysregulated in patients with these disorders. A better understanding of how CSTC dysregulation relates to sleep disorders could lead to more effective treatments, the reviewers say.

Review also confirms subjective reports of poor sleep and insomnia with CSTC-conditions

The reviewers used PubMed, Google Scholar, PsychInfo, and Web of Science to search for relevant English-language articles published before August 2022. They defined OCSDs as including obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), body-focused repetitive behavior (BFRB) disorders, and hoarding disorder. Chronic tic disorders include Tourette syndrome and chronic/persistent motor or vocal tic disorder. The team identified 42 papers: 23 on OCSDs, eight on CTDs, 10 on ADHD, and one on both CTDs and ADHD. They refer to these disorders collectively as CSTC-conditions.

Co-occurring objective sleep movement disorders were consistently reported in adults with CTDs or OCD, and similar subjective findings were documented for children with OCD, ADHD, or CTDs. Although only a small number of studies included polysomnographic data, there was evidence of a sleep disturbance pattern with OCD, BFRB disorders, and CTDs. Subjective sleep latency problems and objective sleep spindle disruption were both common.

"The evidence reviewed in this paper supports a bidirectional, additive increase in sleep and CSTC-condition symptoms," the reviewers write. "In addition to evidence that disordered sleep may be intrinsic to these CSTC-conditions, poor sleep can also impair functional connectivity and may result in structural changes in the fronto-striatal circuitry, likely further exacerbating CSTC-condition symptoms."

Determining treatments for sleep-related complaints in patients with CSTC-conditions

There are three potential approaches to treating sleep disturbances in patients with CSTC-conditions, the team notes: (1) treatment of the condition, which may indirectly treat sleep-related concerns; (2) treatment of sleep, which may indirectly treat symptoms of the CSTC-condition; and (3) treatment of both approaches simultaneously. The most effective approach, however, may differ from person to person, contingent on the specific condition(s) and sleep problems.

The reviewers say careful treatment selection is particularly important for children taking medication for CSTC-conditions. Clinicians must weigh "the potential long-term effects of an altered sleep architecture against the substantial risks of untreated psychopathology, which comes with its own significant sequelae," they emphasize. "Identifying medications that mitigate core symptoms while stabilizing or improving sleep architecture, as opposed to exacerbating existing sleep disturbances, is a critical avenue for future research."

As an example, the reviewers cite selective serotonin reuptake inhibitors (SSRIs). These medications are the first-line treatment for OCD and BDD, but they delay the onset of rapid eye movement (REM) sleep and decrease the proportion of time spent in REM sleep. "It will be important to understand if the degree to which an SSRI is helpful in treating OCD symptoms is moderated by its (positive or negative) impact on sleep architecture," the authors note. "Additionally, it will be important to explore whether these SSRI-associated sleep-related atypicalities are solely secondary to the SSRI, or perhaps would have been likely to emerge independently and secondary to the CSTC-condition itself."

Read Article: Disrupted Cortico-Striato-Thalamo-Cortical Circuitry and Sleep Disturbances in Obsessive-Compulsive Spectrum, Chronic Tic, and Attention Deficit-Hyperactivity Disorders

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, and data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health.

###

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions, and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.